


TRANSLATIONAL TARGET VALIDATION

The Path to Better Drugs?

Tuesday 20 June, 2017 | 09:00-17:00
Wellcome Genome Campus Conference Centre
Hinxton, Cambridgeshire, CB10 1RQ

DISCOVERY FROM CHARLES RIVER



DP Discovery Pathway

Ch Chemistry

B/D Biology/Discovery Technologies

DIP DMPK/Pharmacology/Safety/In Vivo Models

Recognising that the increasing access to human genetic data and the rise of CRISPR/Cas9 has led to rapid changes in the field of target validation, we are bringing together researchers who share an interest in this important foundational step in the drug discovery process. Charles River is pleased to host this 1-day symposium, where we'll network with industry leaders, share best practices, review case studies, and discuss the future of translational target discovery.

We hope you enjoy this unique opportunity to interact with key scientists and learn about the latest advancements and technologies enabling translational target validation.

AGENDA

- 08:00-09:00 **Registration and Breakfast**
- 09:00-09:10 **Welcome and Opening Remarks**
George McAllister, PhD
Senior Director, Discovery - Charles River
- SESSION 1 ADVANTAGES OF A TRANSLATIONAL APPROACH**
- 09:10-09:45 **Tagrisso (Osimertinib): The Journey of Discovery**
Jonathan Orme, BSc
Associate Principal Scientist - Astra Zeneca
- 09:45-10:20 **Optimization of Potent and Selective ATM Inhibitors Suitable for a Proof-of-Concept Study in HD Models**
Perla Breccia, PhD
Team Leader, Medicinal Chemistry - Charles River
- 10:20-10:50 **Networking Refreshment Break**
- 10:50-11:25 **Phenotypic Activity Driven Target Identification**
Professor Paul Wyatt, PhD, FRSE
Head of Drug Discovery Unit, Director of the Wellcome Centre for Anti-Infectives Research - University of Dundee
- 11:25-11:45 **Panel Discussion**
Moderator: George McAllister
Panelists: Jonathan Orme, Perla Breccia, Paul Wyatt, Martin O'Rourke

KEYNOTE ADDRESS

- 11:45-12:30 **Fortune Favours the Prepared Mind - The XO1 Story**
Jim Huntington, PhD
Professor of Haemostasis - University of Cambridge

- 12:30-13:40 **Lunch**

SESSION 2 RECENT DEVELOPMENTS AND FUTURE DIRECTIONS

- 13:40-14:15 **RNAi and CRISPR/Cas9 Based *In Vivo* Models for Drug Discovery**
Prem K. Premsrirut, MD, PhD
Founder, Chief Executive Officer - Mirimus
- 14:15-14:50 **"Click and Play" Protein Degradation and Chemical Biology in Cells**
Christopher N. Johnson, PhD
Senior Director of Medicinal Chemistry - Astex
- 14:50-15:20 **Networking Refreshment Break**
- 15:20-15:55 **Improving Target Identification and Prioritisation through Open Targets: an Integrated Programme of Experiments and Bioinformatics**
Ian Dunham, DPhil
Scientific Director - Open Targets
- 15:55-16:30 **Ventures into New Target Space: Drugging the DUB's**
Tim Harrison, PhD
Vice President, Drug Discovery - Almac Discovery
- 16:30-16:50 **Panel Discussion**
Moderator: George McAllister
Panelists: Jim Huntington, Prem K. Premsrirut, Chris Johnson, Ian Dunham, Jamil Aarbiou
- 16:50-17:00 **Closing Remarks**
David Fischer, PhD
Executive Director, Biology DMPK - Charles River